



National survey on the management and information practices of patients with wet AMD

Marie-Laure Le Lez (1), Bénédicte Briend (2), Hélène Massé (3), Eric Fourmaux (4), Pierre Griffon (5), Franck Rumen (6), Salomon-Yves Cohen (7).




(1) Tours University Hospital, (2) OSIRIS - Centre Rétine Anjou - Angers, (3) Nantes University Hospital, (4) Centre Ophtalmologique Palais Gallien - Bordeaux, (5) Sainte-Marie Hospital - Paris, (6) Visiopole - La Rochelle, (7) Centre Ophtalmologique d'Imagerie et de Laser - Paris

Objective

According to the WHO, AMD is the world's third leading cause of visual impairment and accounts for almost 9% of all causes of blindness. **Our work aimed to collect information practices with a multicentric survey on patients suffering from wet AMD.**

Materials and methods

Two types of questionnaires, developed by a committee of seven ophthalmologists and a psychologist to collect data at one (M + 1) or twelve (M + 12) months after diagnosis. The assessed criteria focused on patient's profile, their management, their understanding and experience versus the disease and the treatment.



Conclusion

This survey demonstrated a gap between the information provided by the medical staff from one side and the apprehension towards the injection and the patient's experience on the other.

Conflicts of interest : Le Lez, M-L. Novartis, Bayer / Masse, H. Novartis, Allergan, Bayer / Cohen, S-Y. Allergan, Bayer, Novartis, Roche, Théa, Tilak Healthcare / Briend, B. Novartis, Bayer, Allergan / Rumen, F. Novartis, Bayer / Fourmaux, E. Allergan, Bayer, Novartis